Association of Circulating Robo4 with Obesity, Hypertension and Atherosclerotic Plaque Burden
Thrombosis and Haemostasis · 01.08.2025 · 125 (08) · 817-820
DOI: 10.1055/a-2437-6308 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.08.2025. Verfasst von Nikolaos I Vlachogiannis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Hellenic Foundation for Research and Innovation, Alexander S. Onassis Public Benefit Foundation.
Abstract (Originalsprache)
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide.[ 1 ] Type 2 diabetes mellitus (T2DM), which is still associated with significant disability and mortality in 2024,[ 2 ] is one of the major risk factors for ASCVD development.[ 3 ] T2DM prevalence is increasing, primarily due to the ongoing obesity pandemic,[ 4 ] with recently published estimates supporting that more than 1.3 billion people will be affected by diabetes mellitus until 2050.[ 2 ] Vascular complications, including atherosclerosis and diabetic nephropathy, comprise major sources of disability and mortality among individuals with T2DM,[ 5 ] whereas endothelial dysfunction is the main pathophysiological mechanism underlying diabetic vascular disease.[ 6 ] Roundabout guidance receptor 4 (Robo4) is an endothelial-specific receptor that regulates endothelial cell (EC) junctional integrity and vascular permeability,[ 7 ] [ 8 ] as well as EC-mediated inflammatory responses[ 9 ] and angiogenesis,[ 7 ] [ 8 ] all of which are central pathogenetic mechanisms in diabetic vascular complications and ASCVD. Moreover, we have previously shown that mice lacking Robo4 exhibit more severe pancreatic damage and faster development of diabetes when subjected to the multiple low-dose streptozotocin model of diabetes.[ 10 ] Based on the above, in the current study, we aimed to explore the potential value of circulating Robo4 (soluble Robo4, sRobo4) as a marker of endothelial dysfunction and vascular disease in individuals with or without T2DM. Forty-three individuals with T2DM and 27 nondiabetic control individuals (control) of similar age and sex were included in the study. All study participants were free of cardiovascular disease (CVD), chronic renal disease, as well as of any chronic inflammatory disease at the time of inclusion in the study. The study was approved by the Laiko Hospital Ethics Committee and all individuals provided informed consent in accordance with the Declaration of Helsinki. All study participants underwent blood sampling after overnight fasting and a detailed medical history was recorded for every individual, including anthropometric assessment, history of CVD risk factors, and detailed biochemistry profile of liver and renal function markers, markers of systemic inflammation and cholesterol levels. Blood pressure (BP) was also measured twice in both arms in the supine position by a trained physician and estimated glomerular filtration rate (eGFR) was determined with the MDRD (Modification of Diet in Renal Disease) equation.[ 11 ] Moreover, subclinical atherosclerosis, as assessed by nonstenotic plaque burden, was measured by standard higher resolution ultrasound in the femoral and carotid arterial bed; all measurements were performed by a single experienced operator blinded to the medical history of the study participants (more details in previous works[ 12 ]). sROBO4 was measured in the plasma using a commercially available ELISA kit (EH394RB, Invitrogen) according to manufacturer's instructions. For the statistical analysis of the data, normality of continuous variables was assessed by Kolmogorov–Smirnov and Shapiro–Wilk tests. Presence of outliers was examined with Rout test ( Q = 1%). Comparison of continuous variables between two groups was performed by independent samples t -test or Mann–Whitney U test when not normally distributed. Correlation between continuous variables was examined by Spearman's rank test. Finally, to examine the association of sRobo4 levels with higher atherosclerotic burden, we utilized a binary logistic regression model with higher atherosclerotic burden as dependent variable (0–1 atherosclerotic plaques = 0, ≥2 atherosclerotic plaques = 1). Statistical significance was set at p < 0.05. sROBO4 was below the detection limit of the assay in 7/43 individuals with T2DM and 8/27 control individuals ( p = 0.24), resulting in a final cohort of 36 T2DM and 19 control individuals with available sRobo4 measurements. Moreover, two individuals with T2DM and four control individuals were identified as outliers. The final cohort ( n = 49) consisting of 34 individuals with T2DM and 15 control individuals was still balanced for age (T2DM: 65.6 ± 8.7 vs. control: 65.7 ± 9.2 years, p = 0.975) and sex (T2DM: 41.2% vs. control: 60.0% male, p = 0.352). Demographics and clinical characteristics of the study cohort are presented in [ Table 1 ]. sROBO4 was comparable between individuals with T2DM and control individuals (T2DM: 1.54 ± 1.19 vs. control: 1.59 ± 0.77 ng/mL, p = 0.46; [ Fig. 1A ]). Fig. 1 Levels and clinical associations of Robo4. ( A ) Bar-chart showing the levels of sRobo4 in the plasma of nondiabetic control individuals (control) and individuals with type 2 diabetes mellitus (T2DM). Outliers (control [ n = 4] and T2DM [ n = 2]) assessed by Rout's test with Q = 1% were removed. ( B , C ) Scatter-plot showing the correlation of Robo4 with body mass index ( B ) and with estimated glomerular filtration rate (eGFR, C ). ( D , E ) Bar charts showing the levels of sRobo4 in the plasma of individuals with or without arterial hypertension ( D ) and with higher (≥2 atherosclerotic plaques) or lower (0–1 atherosclerotic plaques) atherosclerotic burden ( E ). Lines in bar charts correspond to mean ± standard error of the mean (SEM). p -Values in ( A , D , E ) were derived by Mann–Whitney U test and correlation coefficient in B , C by Spearman's rank correlation test. ( F ) Forrest plot showing the odds ratio and 95% confidence intervals for the association of sRobo4 (log10-transformed) with higher atherosclerotic burden. The values were derived by binary logistic regression analysis with higher atherosclerotic burden as the dependent variable and sRobo4 and each variable shown in the respective line as independent variables. The top line corresponds to univariable analysis including only sRobo4 as independent variable. Group refers to T2DM versus control. The x -axis is log2 transformed for visual clarity. p -value for the association of sRobo4 (log10-transformed) with the presence of ≥ 2 atherosclerotic plaques: unadjusted: p
Autor:innen und Institutionen
- Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- First Department of Propaedeutic Internal Medicine and Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, Greece.
- Cardiovascular Prevention and Research Unit, Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
ORCID-Profile: Nikolaos I Vlachogiannis
Förderung
- Hellenic Foundation for Research and Innovation
- Alexander S. Onassis Public Benefit Foundation
Zitieren
APA
Vlachogiannis, N. I., Legaki, A. I., Kassi, E., Mikelis, C. M., Tentolouris, N., Sfikakis, P. P., Protogerou, A. D., & Chatzigeorgiou, A. (2025). Association of Circulating Robo4 with Obesity, Hypertension and Atherosclerotic Plaque Burden. Thrombosis and Haemostasis, 125(08), 817-820. https://doi.org/10.1055/a-2437-6308
Vancouver
Vlachogiannis NI, Legaki AI, Kassi E, Mikelis CM, Tentolouris N, Sfikakis PP, et al. Association of Circulating Robo4 with Obesity, Hypertension and Atherosclerotic Plaque Burden. Thrombosis and Haemostasis. 2025;125(08):817-820. doi:10.1055/a-2437-6308
BibTeX
@article{Vlachogiannis2025,
author = {Vlachogiannis, Nikolaos I and Legaki, Aigli-Ioanna and Kassi, Eva and Mikelis, Constantinos M and Tentolouris, Nikolaos and Sfikakis, Petros P and Protogerou, Athanase D and Chatzigeorgiou, Antonios},
title = {Association of Circulating Robo4 with Obesity, Hypertension and Atherosclerotic Plaque Burden},
journal = {Thrombosis and Haemostasis},
year = {2025},
volume = {125},
number = {08},
pages = {817--820},
doi = {10.1055/a-2437-6308}
}
EUVIMED